Berkle Sheldon 4
4 · Altus Pharmaceuticals Inc. · Filed Feb 2, 2007
Insider Transaction Report
Form 4
Berkle Sheldon
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2007-02-01$18.25/sh−9,750$177,938→ 8,000 total - Exercise/Conversion
Common Stock
2007-02-01$3.92/sh+9,750$38,220→ 17,750 total - Exercise/Conversion
Stock Option (Right to buy)
2007-02-01−9,750→ 513,443 totalExercise: $3.92From: 2005-05-09Exp: 2015-05-08→ Common Stock (9,750 underlying)
Footnotes (2)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Berkle on August 30, 2006.
- [F2]One quarter of these options vested on May 9, 2006, and thereafter an additional 1/48th of the total underlying option grant vests on a monthly basis, such that all options will be vested after four years. In addition, all of these options are immediately exercisable for shares of restricted stock, which are subject to a repurchase right by the Issuer that lapses based on the vesting schedule set forth in the previous sentence.